Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDialysis/Renal ReplacementAetna Dialysis Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0541

    Dialysis

    Customize your policy alerts

    Sign up for Aetna Policy 0541 alerts

    Get alerted when Policy 0541 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, coverage, and coding stance for hemodialysis, home hemodialysis, and peritoneal dialysis services, equipment, and supplies for members with renal failure or end-stage renal disease.

    Policy Summary
    PayerAetna
    PolicyDialysis (Clinical Policy Bulletin)
    Policy CodePolicy 0541
    Change TypeNo material change
    Effective DateJun 26, 2001
    Last ReviewAug 10, 2023
    Next Review DateJun 13, 2024
    Key ActionObtain and document a physician prescription and training/competency when requesting home hemodialysis and related equipment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Up to 3x/weekDialysis sessions considered medically necessary
    >3x/weekAllowed when specific refractory conditions present
    NxStage, TabloPortable/home systems accepted
    1 monthEmergency reserve supplies allowance
    06/26/2001Original effective date
    06/13/2024Next scheduled review

    Coverage and Medical Necessity Criteria

    Medical Necessity Criteria

    Medically necessary when ALL of the following are met:

    Routine dialysis frequency: Hemodialysis or intermittent peritoneal dialysis for renal failure up to 3 times per week.<=3 sessions/week

    Aetna considers hemodialysis or intermittent PD necessary up to 3 times/week.

    More frequent dialysis indications: Hemodialysis or intermittent peritoneal dialysis performed more than 3 times per week for renal failure when ONE OR MORE of the following refractory conditions are present: hyperkalemia, hypophosphatemia, pregnancy, fluid overload, acute pericarditis, congestive heart failure, pulmonary edema, or severe catabolic state.>3 sessions/week when refractory

    Conditions must be refractory to dialysis 3 times per week.

    Policy Summary
    PayerAetna
    PolicyDialysis (Clinical Policy Bulletin)
    Policy CodePolicy 0541
    Change TypeNo material change
    Effective DateJun 26, 2001
    Last ReviewAug 10, 2023
    Next Review DateJun 13, 2024
    Key ActionObtain and document a physician prescription and training/competency when requesting home hemodialysis and related equipment.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCPT / HCPCS / ICD-10 CodingProvider Documentation, Prior Authorization, and Billing GuidancePolicy Background and ScopeKey DefinitionsPolicy Dates and Revision History
    Home hemodialysis — general requirements:
    Home hemodialysis when prescribed by a physician; treatments must be administered under physician prescription and performed by a trained and qualified person deemed competent by the prescribing physician.
    physician prescription and trained operator

    FDA-cleared portable/home systems (eg, NxStage System One, Tablo) are acceptable alternatives for home hemodialysis.

    Home hemodialysis — equipment and supplies: Home dialysis equipment and supplies considered medically necessary include dialysis delivery systems, dialyzers, blood pumps, heparin infusion pumps, monitoring devices, water purification systems (either deionization or reverse osmosis, but not both simultaneously), water softening where needed, and listed consumable supplies (eg, tubing, needles, sterile saline, heparin, fistula cannulation sets, dialysate and testing supplies).equipment as listed

    Medicare primary coverage of equipment typically begins after first 30 months; Aetna usually covers on a rental basis during the first 30 months.

    Professional staff for home hemodialysis: Professional staff to assist home hemodialysis is medically necessary when ALL of the following are met: (1) member is stable on dialysis per National Kidney Foundation criteria; AND (2) member has good functioning vascular access; AND (3) member has medical contraindications to leaving home for hemodialysis; AND (4) member or non-professional caregiver is unable to perform home hemodialysis following training.all conditions required

    Periodic skilled nursing monitoring per a physician-prepared care plan is included.

    Evidence summaries and implied coverage considerations

    Clinical context and evidence summaries relevant to coverage decisions for home hemodialysis, bioengineered access, combined RAAS blockade, and DCB angioplasty.

    Standard dialysis frequency (coverage implication): Routine coverage supports thrice-weekly hemodialysis or intermittent PD; escalation beyond 3 times/week should be limited to documented refractory indications (eg, hyperkalemia, pregnancy, fluid overload) and justified in prior authorization or clinical documentation.

    Supports limiting routine coverage to 3x/week unless documented indication present.

    Home hemodialysis evidence and implications: Feasibility and single-arm/interventional studies (eg, NxStage and Tablo IDE/trials) demonstrate viable Kt/V delivery, improved recovery time and depressive symptoms, and acceptable safety in selected cohorts; larger controlled data (eg, FREEDOM cohort) are ongoing — coverage supported when device is FDA-cleared, prescribed by a physician, and training/competency documented.

    Randomized evidence limited; document prescription and operator competency.

    Bioengineered human acellular vessel — evidence context: Phase II single-arm studies (n=60) report acceptable safety and variable patency (eg, primary patency ~63% at 6 months, secondary patency ~97% at 6 months) supporting further study but not definitive comparative effectiveness; payer consideration may treat as investigational absent RCT data.

    Further RCTs needed to establish comparative benefit.

    Combined RAAS blockade — evidence context: Systematic review of 9 studies (13,050 dialysis patients) suggests combined RAAS blockade may lower all-cause mortality (OR 0.71) but increases hypotension risk; clinical judgment required and monitoring for hypotension is important when considering use in dialysis patients.

    Balance potential mortality reduction against hypotension risk.

    DCB angioplasty — heterogenous evidence: Systematic reviews and meta-analyses provide conflicting findings: some pooled (RCTs and cohorts) report improved 6- and 12-month patency with DCB, whereas RCT-only meta-analyses and multicenter trials have not consistently shown significant patency benefit; benefit remains uncertain and may depend on lesion type and trial selection.

    Coverage decisions may require case-specific rationale and prior authorization due to inconsistent RCT evidence.

    Drug-coated balloon angioplasty — evidence summary

    Coverage considerations for drug-coated balloon angioplasty:

    DCB angioplasty evidence: Randomized trials and systematic reviews have produced inconsistent results: pooled analyses including cohort studies suggest improved 6- and 12-month primary patency with DCB versus conventional balloon angioplasty, but an RCT-only meta-analysis of 11 RCTs (487 DCB, 489 CBA) did not show statistically significant improvement in 6- or 12-month target lesion primary patency; multicenter trials have been negative.

    Requests for DCB should include lesion-specific rationale and cited trial evidence given inconsistent benefit.

    Bio-impedance monitoring (BCM) — evidence summary

    Coverage considerations for multiple-frequency bio-impedance devices:

    BCM evidence summary: Randomized trials of the Fresenius Body Composition Monitor (5 RCTs, 904 participants) showed reductions in absolute and relative over-hydration versus standard clinical assessment, with possible modest effects on intermediate outcomes (eg, systolic BP) but no demonstrated mortality benefit; economic evaluations give mixed cost-effectiveness results depending on inclusion of dialysis costs; NICE concluded evidence insufficient to recommend routine adoption.

    When billing for BCM, document device used, intermediate outcomes assessed, and clinical rationale due to limited evidence for hard outcomes.

    PD peritonitis prevention — evidence summary

    Coverage considerations for antimicrobial strategies to prevent PD peritonitis:

    Antimicrobial prevention evidence: A Cochrane review of 39 RCTs (4,435 patients) found limited and often low-quality evidence: pre-/peri-operative IV vancomycin may reduce early peritonitis and antifungal prophylaxis reduces fungal peritonitis after antibiotics; nasal or topical antibiotics have uncertain effects on peritonitis and exit-site infection.

    Document prior use of evidence-based perioperative strategies before considering alternative prophylactic approaches; evidence quality often low.

    Nicotinic acid for hyperphosphatemia — evidence summary

    Coverage considerations for nicotinic acid and related compounds for hyperphosphatemia:

    Nicotinic acid efficacy and safety: Meta-analysis of small, short-duration trials showed significant short-term reductions in serum phosphorus (at 4–8 weeks) and in calcium × phosphorus product, but notable adverse event rates (eg, diarrhea overall AE incidence ~41%); safety and longer-term efficacy remain uncertain.

    If considered, monitor lipid profile and adverse events; evidence limited to small trials.

    Peritoneal dialysis for heart failure — evidence summary

    Coverage considerations for peritoneal dialysis in heart failure:

    PD for refractory heart failure evidence: Nonrandomized studies (31 studies, n≈902) report symptomatic improvement, increased LVEF in many series, and reduced hospitalizations for diuretic-resistant heart failure, but no randomized trials; guidelines do not recommend PD as routine therapy for heart failure and comparative evidence versus extracorporeal ultrafiltration or hemodialysis is inadequate.

    PD may be considered on case-by-case basis for diuretic-resistant HF but requires careful documentation of rationale and expected benefit.

    Wearable hemodialysis devices — evidence summary

    Coverage considerations for wearable hemodialysis devices:

    Wearable HD evidence: Pilot studies (eg, WAK pilot n=8) demonstrate feasibility with measurable solute clearance and manageable short-term safety signals, but data are limited and long-term safety and effectiveness are unestablished; horizon scans and reviews call for larger long-term studies before routine use.

    Wearable devices (eg, listed HCPCS E1632/E1635) may be considered investigational or not covered depending on payer stance and code listings.

    Vitamin E–coated membranes — evidence summary

    Coverage considerations for vitamin E–coated membranes (ViE-m):

    ViE-m evidence: Systematic reviews and meta-analyses (eg, 60 studies) indicate ViE-m may reduce erythropoietin resistance index and selected inflammatory/oxidative biomarkers (eg, IL-6) but do not consistently improve hemoglobin, weekly EPO dose, lipid profile, dialysis adequacy, or hard clinical outcomes; high-quality trials with clinical end-points are needed.

    Documented biomarker improvements do not equate to proven clinical outcome benefit.

    HIF-PHI agents — evidence summary

    Coverage considerations for HIF-PHI agents in CKD anemia:

    HIF-PHI efficacy and safety: Phase-III trials and network/meta-analyses show HIF-PHIs generally non-inferior to ESAs for hemoglobin response and have effects on iron metabolism (decreased hepcidin/ferritin/TSAT and increased transferrin/TIBC), but agent-specific safety signals (eg, thrombosis and hypertension with roxadustat) and regulatory decisions vary; long-term safety and optimal patient selection remain uncertain.

    Coverage should consider regulatory status, agent-specific safety data, and need for monitoring (eg, iron parameters).

    Evidence summaries — assorted meta-analyses and trial findings

    Evidence-based conclusions and clinical considerations extracted from systematic reviews and meta-analyses:

    ViE-m conclusions: Meta-analyses show ViE-m may reduce EPO resistance index and decrease selected inflammatory and oxidative biomarkers, but do not demonstrate consistent benefits on anemia, dialysis adequacy, or hard clinical outcomes; further high-quality trials with clinical endpoints are needed.
    HIF-PHIs vs ESAs conclusions: HIF-PHIs raise hemoglobin comparably to ESAs and alter iron metabolism with heterogeneity across agents; some agents rank higher for Hb response but also show increased risks for thrombosis and hypertension in some analyses; long-term safety and agent-specific risk profiles warrant cautious consideration.

    Consider regulatory status and agent-level safety evidence when evaluating coverage.

    IL-6 prognostic association: Higher IL-6 levels are associated with increased cardiovascular (HR ~1.55) and all-cause mortality (HR ~1.11) in dialysis patients, particularly hemodialysis, though publication bias and heterogeneity limit certainty.

    IL-6 may be of prognostic interest but utility for guiding routine coverage decisions is limited.

    Aetna does not consider backup equipment or precautionary spare supplies to be medically necessary when provided solely in anticipation of need for substitution or replacement. Specifically, spare deionizing tanks and similar precautionary items are not considered medically necessary. Emergency reserve supplies are an exception when provided at initiation of dialysis: up to a one-month supply as a one-time allowance is considered medically necessary to cover short-term increases in use or delivery delays. Also note that charges for repair and maintenance of rented equipment are included in rental fees and will be denied if billed separately.

    Randomized trials and multicenter studies have not consistently demonstrated a patency advantage for drug-coated balloon (DCB) angioplasty versus conventional balloon angioplasty (CBA) for hemodialysis access stenosis. A pooled analysis of 11 RCTs (487 DCB, 489 CBA) found no statistically significant difference in 6- or 12-month target lesion primary patency, and multicenter trials cited in reviews also failed to show improved patency rates. Given these inconsistent results, the evidence does not establish routine superiority of DCB angioplasty for dialysis access and supports careful case-by-case consideration.

    Guidance from the National Institute for Health and Care Excellence (NICE, 2017) concluded there is insufficient evidence to recommend routine adoption of the Body Composition Monitor (BCM) to guide fluid management in people with chronic kidney disease receiving dialysis. NICE also found inadequate validation or clinical-outcome data to support routine use of the InBody S10 or MultiScan 5000 for this purpose.

    The provided document excerpts do not list explicit, universal coverage exclusions for several interventions; rather, they summarize uncertainty in benefits and note the need for higher-quality evidence. For example, systematic reviews of vitamin E–coated membranes and network meta-analyses of HIF-PHIs report mixed or incomplete evidence on hard clinical outcomes, but the text does not present a single blanket exclusion statement for these technologies in the excerpts shown.

    Clinical Policy Bulletins are intended to assist in administering plan benefits but do not constitute offers of coverage or medical advice. This bulletin provides only a partial, general description of plan or program benefits and does not constitute a contract; it cannot guarantee coverage or specific clinical outcomes. Treating providers remain solely responsible for medical advice and treatment.

    Peridex filter sets for peritoneal dialysis and certain precautionary ultrafiltration monitoring devices are considered not medically necessary when provided solely as spare or anticipatory equipment. The policy also states that short-wave diathermy machines are not covered for home use. Charges for repair of rented equipment are included in rental fees and will be denied if billed separately.

    CPT / HCPCS / ICD-10 Coding

    Hemodialysis CPT/HCPCSmixedCovered
    90935Hemodialysis procedure with single evaluation by a physician or other qualified health care professional.
    90937Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription.
    90999Unlisted dialysis procedure, inpatient or outpatient.
    99512Home visit for hemodialysis.
    E1632Wearable artificial kidney, each.
    E1629Tablo hemodialysis system for the billable dialysis service.
    E1590Hemodialysis machine.
    E1615Deionizer water purification system, for hemodialysis.
    E1610Delivery and/or installation charges for hemodialysis equipment.
    Peritoneal Dialysis CPT/HCPCSmixedCovered
    90945Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies), with single physician evaluation [CAPD, CCPD].
    90947Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated physician evaluations, with or without substantial revision of dialysis prescription [CAPD, CCPD].
    90999Unlisted dialysis procedure, inpatient or outpatient.
    E1592Automatic intermittent peritoneal dialysis system.
    E1594Cycler dialysis machine for peritoneal dialysis.
    E1630Reciprocating peritoneal dialysis system.
    Dialysis supplies HCPCSHCPCSCovered
    A4680Activated carbon filters for hemodialysis, each.
    A4690Dialyzer (artificial kidneys), all types, all sizes, for hemodialysis, each.
    A4706Bicarbonate concentrate, solution, for hemodialysis, per gallon.
    A4730Fistula cannulation set for hemodialysis, each.
    A4720Dialysate solution, any concentration of dextrose, fluid volume greater than 249 cc but <=999 cc, for peritoneal dialysis.
    Covered ICD-10 codesICD-10Covered
    N18.6End stage renal disease.
    E87.5Hyperkalemia.
    E83.39Other disorders of phosphorous metabolism [Hypophosphatemia].
    E87.70Fluid overload.
    I50.1Heart failure.
    HCPCS codes not covered (listed)HCPCSNot Covered
    E1632Wearable artificial kidney, each.
    E1635Compact (portable) travel hemodialyzer system.
    Dialysis frequency — usual maximum and exceptions
    Usual maximum frequencyHemodialysis or intermittent peritoneal dialysis medically necessary up to 3 times per week
    Allowed exceedance>3 times/week may be medically necessary for refractory conditions (hyperkalemia, hypophosphatemia, pregnancy, fluid overload, acute pericarditis, congestive heart failure, pulmonary edema, severe catabolic state)
    Condition for >3x/weekConditions must be refractory to dialysis 3 times per week

    Provider Documentation, Prior Authorization, and Billing Guidance

    Prior Authorization

    Obtain prior authorization for dialysis services and equipment when selection criteria apply

    Certain dialysis procedure and durable medical equipment CPT/HCPCS codes are listed as covered when Aetna selection criteria are met; providers should obtain prior authorization for services and equipment subject to coverage criteria (examples include 90935, 90937, 90945, 90947, 90999, and HCPCS such as E1590, E1610, E1615, E1629, E1632, S9335).

    • Prior authorization recommended when coverage is contingent on selection criteria being satisfied.
    • Covered codes include hemodialysis CPTs (90935, 90937, 90999), peritoneal dialysis CPTs (90945, 90947), and multiple HCPCS for equipment (E1590, E1610, E1615, E1629, E1632) and per-diem home therapy (S9335).
    Prior Authorization

    Document physician prescription, training, and indication for home or increased‑frequency dialysis

    Prior authorization or documented justification may be required for home hemodialysis and for dialysis delivered more frequently than the standard thrice-weekly schedule; documentation must include the physician's prescription and evidence of training/competency of the person performing treatments.

    • Physician prescription required for use of FDA-cleared home devices (eg, NxStage, Tablo) and for home treatments.
    • Document that treatments are performed by a trained and qualified person deemed competent by the prescribing physician.
    • When requesting >3 sessions/week, include clinical indication showing the condition is refractory to dialysis 3 times/week (eg, hyperkalemia, fluid overload, pregnancy, acute pericarditis, CHF, pulmonary edema, severe catabolic state).
    Prior Authorization

    Include indication and rationale for DCB angioplasty requests

    Requests for drug‑coated balloon (DCB) angioplasty should include clinical indication and explicit rationale because randomized trials and multicenter data have not consistently shown improved patency versus conventional balloon angioplasty.

    • Provide lesion‑specific rationale and citation of supporting evidence when seeking authorization for DCB angioplasty.
    • Be aware that pooled RCT analyses (11 RCTs) did not show significant 6‑ or 12‑month primary patency benefit for DCB versus conventional balloon angioplasty.
    Note

    No explicit PA rules in these excerpts — consult full policy

    No explicit prior authorization requirements are specified in the cited excerpts; consult the full policy and plan documents for plan‑level prior authorization rules that may apply.

    • The provided sections do not list additional PA rules or affected billing codes.
    • Local plan contracts or benefit documents may impose separate PA requirements.
    Note

    Consult full policy and plan documents for specific prior authorization requirements

    Prior authorization rules are not fully enumerated in the partial bulletin; providers must consult the complete Clinical Policy Bulletin and member plan documents for specific prior authorization requirements.

    • Clinical Policy Bulletins are a partial description of plan benefits and do not replace plan or contract language.
    • Confirm PA requirements with the payer before delivering services when in doubt.
    Note

    Operational guidance — CPB is administrative guidance, not a coverage contract

    Operational note: Clinical Policy Bulletins are administrative guidance and do not constitute a contract; treating providers remain responsible for medical advice and treatment decisions.

    • Use the CPB to inform benefit administration but verify coverage under the member's contract.
    • Providers are independent and responsible for clinical care.
    Step Therapy

    Justify escalation to >3 sessions/week with documented refractory indication

    Escalation from standard thrice‑weekly dialysis to more frequent dialysis (>3x/week) requires documentation that the indicated refractory clinical condition is present and not controlled by dialysis three times per week.

    • Allowed refractory indications include hyperkalemia, hypophosphatemia, pregnancy, fluid overload, acute pericarditis, congestive heart failure, pulmonary edema, or severe catabolic state.
    • Include objective documentation demonstrating failure of adequate control with 3x/week dialysis when requesting increased frequency.
    Step Therapy

    Document prior use of evidence‑based PD peritonitis prevention strategies before advanced interventions

    For prevention of PD peritonitis, document prior use of evidence‑based strategies (for example, peri‑operative IV vancomycin when indicated and antifungal prophylaxis after antibiotic use) before advancing to alternative or uncertain interventions.

    • Document prior application of standard perioperative and topical measures and the outcomes.
    • Record rationale for considering nasal antibiotic strategies given uncertain benefit in trials.
    Note

    No step therapy algorithms provided in these excerpts

    No step therapy algorithms are described in the provided excerpts.

    • Providers should not assume formal step therapy sequences from these sections; verify with full policy if a step process exists.
    Note

    Confirm coverage under the member's contract — CPB does not guarantee payment

    Operational guidance from the CPB: participating providers are independent contractors; the bulletin assists benefit administration but does not guarantee coverage—confirm coverage under the member's contract.

    • Clinical Policy Bulletins are not offers of coverage and do not constitute a contract.
    • Absence of contractual language in the CPB may affect payment decisions under plan terms.
    Documentation Required

    Ensure physician prescription and physician‑prepared care plan for home therapies and skilled nursing

    For home therapies, the physician must prescribe treatment and a physician‑prepared care plan is required for skilled nursing monitoring; document the care plan and periodic physician review when billing for skilled nursing visits.

    • Skilled nursing periodic monitoring must follow a care plan prepared and periodically reviewed by a physician.
    • Physician prescription and documented care plan are required when billing home nursing or home hemodialysis services.
    Documentation Required

    Document physician prescription and training/competency for home hemodialysis with FDA‑cleared devices

    When prescribing home hemodialysis using FDA‑cleared home devices (eg, NxStage System One, Tablo), document the physician prescription and evidence of training/competency for the patient or caregiver.

    • Treatments must be administered under a physician's prescription.
    • Record that the person performing treatments is trained and deemed competent by the prescribing physician.
    Documentation Required

    Document BCM device, intermediate outcomes, and rationale when billing for bio‑impedance monitoring

    When billing for multiple‑frequency bio‑impedance monitoring (eg, BCM), document the device used, the intermediate outcomes assessed (such as over‑hydration measures and systolic blood pressure), and the clinical rationale given limited evidence for mortality benefit.

    • Report device make/model (eg, BCM) and measurements before and after implementation.
    • Record rationale for use and any changes to fluid management guided by BCM findings.
    Documentation Required

    You may cite trial or meta‑analysis evidence to support clinical rationale (no specific citation format required)

    Citation of trial or meta‑analysis evidence may be included to support clinical rationale for interventions with uncertain benefit, but the provided excerpts do not prescribe operational documentation requirements for such citations.

    • Include relevant trial citations when justifying use of interventions with mixed evidence (eg, DCB angioplasty, ViE‑m, HIF‑PHIs).
    • Evidence citation alone does not replace specific coverage/authorization requirements.
    Note

    Providers remain responsible for clinical care; CPBs assist benefit administration

    Treating providers remain responsible for medical advice and treatment decisions; Clinical Policy Bulletins assist in benefits administration but do not substitute for clinical judgment or create contractual coverage.

    • Use CPBs to guide benefit interpretation but rely on clinical judgment for patient care.
    • Confirm member coverage details separately from the CPB.
    Billing Rule

    Do not bill separately for repair of rented equipment — repair charges are included in rental

    Charges for repair or maintenance of rented equipment are included in rental fees; submit repair charges separately risks denial because such charges are considered part of rental.

    • Do not bill separately for repair of rented dialysis equipment; those charges will be denied as included in rental charges.
    • If member‑owned equipment is being repaired, rental of replacement equipment is considered medically necessary.
    Denial Risk

    Frequency limits: >3x/week dialysis requires documented refractory indication to avoid denial

    Dialysis delivered more than three times per week is considered medically necessary only for listed refractory conditions; requests for increased frequency without documentation of such indications may be subject to review or denial.

    • Refractory indications include hyperkalemia, hypophosphatemia, pregnancy, fluid overload, acute pericarditis, congestive heart failure, pulmonary edema, and severe catabolic state.
    • Document that the condition is refractory to dialysis 3 times per week when requesting >3x/week treatments.
    Denial Risk

    DCB angioplasty may be denied for lack of demonstrated patency benefit without strong case‑specific evidence

    DCB angioplasty lacks consistent evidence of improved target‑lesion patency in pooled RCT analyses; requests solely to improve patency may be denied unless compelling, lesion‑specific evidence is provided.

    • Meta‑analysis of 11 RCTs (487 DCB, 489 CBA) showed no significant difference in 6‑ or 12‑month primary patency.
    • Multicenter trials have not consistently demonstrated patency benefits with DCB versus conventional angioplasty.
    Note

    No further PA or denial triggers specified in these excerpts

    No additional explicit prior authorization or billing denial triggers are identified in these specific excerpts; follow the PA/billing rules documented elsewhere in the full policy and payer guidelines.

    • These sections do not describe further PA or denial triggers.
    • Confirm local plan requirements for any additional triggers.
    Note

    CPB statements are not guarantees of coverage — verify plan/contract language

    Clinical Policy Bulletins provide partial benefit descriptions and do not guarantee coverage; absence of explicit coverage language in the CPB may lead to denial based on the member's contract terms.

    • Verify coverage under the member's contract; CPBs are not contractual documents.
    • Coverage decisions may depend on plan‑specific language beyond the CPB.

    Policy Background and Scope

    Hemodialysis or intermittent peritoneal dialysis is routinely provided up to 3 times per week for renal failure. Treatments performed more frequently than three times weekly may be considered medically necessary only when one or more refractory clinical conditions are present (for example, refractory hyperkalemia, refractory hypophosphatemia, pregnancy, fluid overload, acute pericarditis, congestive heart failure, pulmonary edema, or severe catabolic state). Home hemodialysis using FDA-cleared portable systems (such as NxStage or Tablo) is accepted when prescribed by a physician and performed by trained, competent personnel with required documentation and care planning.

    Key Definitions

    Home hemodialysis — definition and description
    DefinitionHemodialysis performed in the member's home when prescribed by a physician; includes use of portable/mobile systems and may include skilled nursing monitoring per a physician-prepared care plan
    Prescribing and trainingAll home treatments must be administered under a physician's prescription and performed by a trained and qualified person deemed competent by the prescribing physician
    Examples of systemsIncludes portable/home-capable systems (see device examples: NxStage System One, Tablo)
    Home Hemodialysis Device (examples)
    FDA-cleared examplesNxStage System One (NxStage Medical) and Tablo Hemodialysis System (Outset Medical)
    IndicationsCleared for treatment of acute and/or chronic renal failure in acute/chronic care settings and indicated for home use when prescribed and operated by trained individuals
    Device featuresTablo described as a compact mobile unit on wheels with wireless connectivity and touchscreen guidance; NxStage cleared for home nocturnal and other home hemodialysis modalities
    Bioengineered Human Acellular Vessel — definition and intended use
    DefinitionA tissue-engineered, decellularized human acellular vessel implanted as a hemodialysis access graft intended as an alternative to synthetic (PTFE) grafts
    Intended useImplanted into the arm for hemodialysis vascular access in patients not candidates for fistula
    Evidence summaryPhase II single-arm trials (60 patients) reported safety and variable patency (primary patency ~63% at 6 months; secondary patency 97% at 6 months) and warrant further RCT study
    Drug-Coated Balloon (DCB) Angioplasty — definition and purpose
    DefinitionEndovascular angioplasty using a balloon coated with an anti-proliferative drug intended to reduce restenosis of hemodialysis vascular access stenoses compared with conventional balloon angioplasty
    PurposeAims to decrease re-stenosis rates and improve primary patency of arteriovenous access lesions
    Evidence contextSystematic reviews include RCTs and cohort studies with mixed results; benefit remains uncertain pending further studies
    Drug-coated balloon (DCB) angioplasty — short definition
    Short definition (duplicate)Endovascular balloon angioplasty with an antiproliferative drug coating intended to reduce restenosis of hemodialysis vascular access stenoses
    Context noteRCT-focused meta-analyses have not consistently shown significant patency benefit compared with conventional balloon angioplasty
    Body Composition Monitor (BCM) — definition and clinical role
    DefinitionA multiple-frequency bio-impedance device (eg, Body Composition Monitor) used to estimate fluid status—absolute and relative over-hydration—in dialysis patients
    Clinical roleUsed to guide fluid removal targets by measuring over-hydration compared with standard clinical assessment; RCTs showed reduced over-hydration measures but no demonstrated mortality benefit
    DocumentationWhen billing for BCM use, document device, intermediate outcomes assessed (over-hydration measures, SBP), and rationale given limited evidence for hard outcomes
    HIF-PHI — definition (class of agents)
    Class definitionHypoxia-inducible factor–prolyl hydroxylase inhibitors (HIF-PHIs) are oral small-molecule agents that stimulate endogenous erythropoietin production via HIF activation to treat anemia in CKD
    Clinical contextPhase 3 trials show non-inferiority to ESAs for hemoglobin response; agents vary in effects on iron metabolism and safety signals (eg, thrombosis, hypertension)
    Regulatory noteRegulatory status and agent-specific safety must be considered (eg, FDA declined approval for roxadustat citing safety concerns)
    Vitamin E-coated membranes — definition (ViE-m)
    DefinitionDialyzer membranes coated with vitamin E (ViE-m)
    Intended effectDesigned to reduce oxidative stress and inflammation during hemodialysis; systematic reviews show decreased IL-6 and improved erythropoietin resistance index
    Evidence limitationNo conclusive evidence that ViE-m improves hard clinical outcomes (eg, mortality, dialysis adequacy); high-quality trials with clinical end-points are needed
    HIF-PHI — additional definition entry
    Alternate entry for HIF-PHIHIF-PHIs are small-molecule oral inhibitors of prolyl hydroxylase that activate HIF to increase endogenous erythropoietin production and alter iron metabolism
    Clinical trial evidenceNetwork/meta-analyses show HIF-PHIs and ESAs raise Hb versus placebo; heterogeneity exists across agents for hepcidin and iron parameters
    Safety considerationsSome agents associate with increased thrombosis or hypertension; agent-specific safety profiles should guide coverage decisions
    IL-6 — definition and relevance to mortality risk in dialysis patients
    DefinitionInterleukin-6 (IL-6) is a pro-inflammatory cytokine measurable in serum
    Clinical relevanceHigher IL-6 levels are associated with increased cardiovascular mortality (HR ~1.55) and all-cause mortality (HR ~1.11) in dialysis patients, particularly hemodialysis patients
    Evidence noteMeta-analysis included 28 studies (8,370 patients); results show association but are limited by potential publication bias and heterogeneity

    Policy Dates and Revision History

    2001-06-26Effective date

    Policy became effective.

    2023-08-10Last review

    Policy was last reviewed.

    2024-06-13Next scheduled reviewLatest

    Next review scheduled.